A Randomized, Double-masked, Placebo-controlled Study Assessing the Efficacy and Safety of Privosegtor (OCS-05) in Patients With Optic Neuritis (ON)
Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: f
View:
• Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss.
• Onset of visual loss symptoms in the previous 12 days before first administration of study treatment.
Locations
United States
Texas
Neuro-Eye Clinical Trials
RECRUITING
Houston
Contact Information
Primary
Chief Development Officer
info@oculis.com
617-928-5886
Time Frame
Start Date: 2026-05-28
Estimated Completion Date: 2028-12
Participants
Target number of participants: 210
Treatments
Experimental: Privosegtor
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: Oculis